Dianthus Therapeutics, Inc. /DE/ Logo

Dianthus Therapeutics, Inc. /DE/

Developing selective antibody therapies for severe autoimmune diseases.

DNTH | NDAQ

Overview

Corporate Details

ISIN(s):
US2528281080 (+1 more)
LEI:
Country:
United States of America
Address:
7 TIMES SQUARE, 10036 NEW YORK
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies for severe autoimmune diseases. The company focuses on designing and engineering potentially best-in-class monoclonal antibodies with improved potency, high selectivity, and extended half-lives. Its lead candidate, claseprubart (DNTH103), is an antibody that selectively targets the active C1s complement protein. The pipeline also includes DNTH212, a bifunctional inhibitor targeting Type 1 IFN suppression and B cell modulation. Dianthus's therapeutic approach aims to enable less frequent and more convenient self-administered subcutaneous injections, with the goal of improving clinical outcomes and quality of life for patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Dianthus Therapeutics, Inc. /DE/ filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dianthus Therapeutics, Inc. /DE/

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Dianthus Therapeutics, Inc. /DE/ via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Calliditas Therapeutics Logo
Develops and commercializes novel treatments for rare renal and hepatic diseases like IgA nephropathy.
Sweden CALTX
CALTH. Inc Logo
Develops AI-powered rapid diagnostic solutions for point-of-care and self-testing.
South Korea 402420
CAMBRIDGE NUTRITIONAL SCIENCES PLC Logo
Develops and manufactures diagnostic tests for food sensitivity and gut health.
United Kingdom CNSL
Camp4 Therapeutics Corp Logo
Developing RNA-based therapies to upregulate genes for rare metabolic and CNS disorders.
United States of America CAMP
Camurus Logo
Develops long-acting medicines for severe chronic diseases using advanced drug delivery.
Sweden CAMX
Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.
Japan 4575
Candel Therapeutics, Inc. Logo
Developing off-the-shelf viral immunotherapies to help the immune system fight solid tumors.
United States of America CADL
Can-Fite BioPharma Ltd. Logo
Clinical-stage biopharma developing oral drugs for cancer, inflammatory, liver & metabolic diseases.
United States of America CANF
Can-Fite BioPharma Ltd. Logo
Develops oral small-molecule drugs targeting A3AR for oncology and inflammatory diseases.
Israel CANF
Cannovum Cannabis AG Logo
Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.
Germany 27N0

Talk to a Data Expert

Have a question? We'll get back to you promptly.